An advisory panel to the US Food and Drug Administration on Thursday Voted to recommend booster shot NS For many Americans, it is at least six months after their second dose.
The panel unanimously voted yes on the third shot for people 65 and older, people 18 and older at high risk of severe COVID-19, and people 18 and older whose jobs made a difference. Putting them at risk of COVID-19 infection. these arelast month.
NS COVID-19 vaccines are highly effective In preventing hospitalization and death. Over the summer, as the Delta version took hold in the US, so did the number of cases, hospitalizations, and deaths from COVID-19. People who haven’t been vaccinated accounted for nearly all hospitalizations and deaths – more than 97% as of July.
While the US is already giving some people a booster shot of the Pfizer vaccine, Only 2.5% of people living in low-income countries Have received at least one vaccine dose.
The vote by the FDA panel is not binding, but the agency can accept the recommendation. FDALess than a week later the advisory panel made its recommendation.
The FDA has already granted emergency authorization for a third dose of Moderna Vaccine for some adults who are immunocompromised.
The panel is meeting again on Friday to discuss a booster dose for the Johnson & Johnson COVID-19 vaccine.
more to come.